Post-traumatic stress syndrome is an anxiety disorder that is estimated to impact some eight million Americans annually. Yet, to date, there are no pharmaceutical treatments specifically designed or approved to target symptoms of PTSD.

Investigators at the New York University School of Medicine and the New York University Langone Medical Center, Steven and Alexandra Cohen Veterans Center for the Study of Post-Traumatic Stress and Traumatic Brain Injury reported that subjects diagnosed with PTSD typically possess elevated quantities of endogenous cannabinoid receptors in regions of the brain associated with fear and anxiety. Investigators also determined that many of these subjects experience a decrease in their natural production of anandamide, an endogenous cannabinoid neurotransmitter, resulting in an imbalanced endocannibinoid regulatory system.

Researchers speculated that an increase in the body’s production of cannabinoids would likely restore subjects’ natural brain chemistry and psychological balance. They affirmed, “[Our] findings substantiate, at least in part, emerging evidence that … plant-derived cannabinoids such as marijuana may possess some benefits in individuals with PTSD by helping relieve haunting nightmares and other symptoms of PTSD.”

They concluded: “The data reported herein are the first of which we are aware of to demonstrate the critical role of CB1 (cannabinoid) receptors and endocannabinoids in the etiology of PTSD in humans. As such, they provide a foundation upon which to develop and validate informative biomarkers of PTSD vulnerability, as well as to guide the rational development of the next generation of evidence-based treatments for PTSD.”

Anecdotal evidence and case study reports have increasingly indicated that cannabis may mitigate traumatic memories and anxiety. However, clinical trial data remains unavailable, in large part because US federal officials have blocked investigators’ efforts to study cannabis in PTSD subjects. In 2011 federal administrators halted efforts by investigators at the University of Arizona to complete an FDA-approved, placebo-controlled clinical trial to evaluate the use of cannabis in 50 veterans with treatment-resistant PTSD.

PTSD is also seldom identified as a qualifying condition in states that allow for the physician authorized use of cannabis therapy. (To date, only New Mexico explicitly cites PTSD as a qualifying condition for cannabis treatment, although a handful of other states, like California, allow doctors the discretion to legally recommend marijuana for post-trauma subjects.) In Oregon, lawmakers in the House are considering Senate-approved legislation, SB 281, that would allow PTSD patients to legally consume cannabis under the state’s nearly 15-year-old medical marijuana program.

LD 1229 was introduced earlier in the session by Representative Diane Russell (D-Portland) and 35 co-sponsors. Despite the unprecedented legislative support, the measure faced a challenging work session last week, which initially looked as if it would scuttle the bill entirely.

Fortunately for supporters of ending prohibition, the fight continues on despite the negative recommendation out of committee. Representative Russell and the bill’s supporters intend to take the fight for legalization to the House floor in the coming weeks and they need our help. Thanks to amendments offered by Senators Plummer and Wilson, LD 1229 was revised to contain only a simple referenda component. If the amended bill is approved, it would place the question of whether or not to legalize marijuana on the ballot in Maine this fall. It will be a straight up or down vote on marijuana legalization, regulatory authority will fall to the legislature if the people of Maine vote in favor of this measure.

If you live in Maine, it is more imperative than ever that you reach out to your elected officials and urge them to support LD 1229. Regardless of their opinion on marijuana legalization itself, they should support this legislation which would allow the people of Maine to voice their opinion on this incredibly important issue. Tell your state politicians to “Let the People Decide” and to support LD 1229. Click here to quickly and easily do so.

Whether you live in Maine or not, we encourage you to sign this petition being circulated by the bill’s primary sponsor, Rep. Russell, and help us send a resounding message to lawmakers in Maine that it is time to let the people vote on this issue.

NORML will keep you updated as this legislation moves forward.

Together, we can legalize marijuana in Maine in 2013.

Recent polling data released by Siena Research Institute revealed that 82% of New Yorkers support the medical use of marijuana. Fortunately for New York lawmakers, they can take action to address this issue that’s supported by an overwhelming majority of their constituents. Medical marijuana legislation is currently pending in both Houses of the New York Legislature and these measures have been gaining substantial political support. This legislation is expected to be debated by elected officials in the coming weeks. If you live in New York, click here to quickly and easily contact your state politicians and urge them to support this important legislation.

In addition to medical marijuana, it seems that full legalization will also soon be debated. State Senator Liz Krueger announced her intentions to introduce legislation that would legalize the recreational use and limited cultivation of marijuana. The measure would also allow for the commercial sale of marijuana at retail outlets regulated by the New York State Alcohol Authority.

“It is my intention as a New York State senator to soon introduce a law that would actually decriminalize, regulate and tax marijuana in New York,” stated Sen. Krueger.

NORML will update you when this legislation is introduced.

You can read the full text of the measure here.

NORML will keep you updated as this story develops.

The survey also found that 52% of Americans favor federal legislation that would prevent the federal government from prosecuting people who grow, possess, or sell marijuana in the states that have legalized it. Recently, Representative Dana Rohrabacher (R-CA) introduced the “Respect State Marijuana Laws Act” which would do exactly that. You can click here to easily contact your Representative and urge him or her to support this measure.

Full results of this poll are available here.

Researchers at the University of Michigan, Institute for Social Research analyzed the impact of student drug testing programs in some 250,000 high-school and middle-school students over a 14 year period. Investigators reported that random drug testing programs of the student body and programs specifically targeting student athletes were associated with “moderately lower marijuana use,” but cautioned that drug testing programs overall were “associated with increased use of illicit drugs other than marijuana.”

An estimated 14 percent of middle school students and 28 per cent of US high school students are now subject to some form of drug testing.

Urinalysis, the most common form of student drug testing, screens for the presence of inert drug metabolites (breakdown products), not the actual parent drug. Because marijuana’s primary metabolite, carboxy-THC, is fat soluble, it may be present in urine for days, weeks, or in some cases even months after past use. By contrast, most other illicit drug metabolites are water soluble and will exit the body within a matter of hours. Authors of the study speculated that students subjected to drug screens were switching from cannabis to other illicit drugs which possessed shorter detection times.

“Random SDT (student drug testing) among the general high school student population, as well as middle and high school subgroups targeted for testing, was associated with moderately lower marijuana use; however, most forms of testing were associated with moderately higher use of other illicit drugs, particularly in high school,” the authors concluded. “These findings raise the question of whether SDT is worth this apparent tradeoff.”

Commenting on the findings, the study’s lead author affirmed, “It is clear that drug testing is not providing the solution for substance-use prevention that its advocates claim.”

Previous assessments of student drug testing programs have reported that those subjected to such programs are no less likely to report consuming illicit drugs, tobacco, or alcohol than their peers.

The abstract of the study, “Middle and High School Drug Testing and Student Illicit Drug Use: A National Study 1998–2011,” is available online here.

Here is a summary of the study from the website diabetes.co.uk:

Cannabis may prevent development of type 2 diabetes

A new study has revealed that smoking cannabis may help protect against type 2 diabetes after researchers in the US found that regular users of the drug have better blood sugar control.

Murray Mittleman, of the Cardiovascular Epidemiology Research Unit at the Beth Israel Deaconess Medical Centre in Boston, analysed data on almost 5,000 patients who were quizzed about their use of recreational drugs as part of the National Health and Nutrition Survey between 2005 and 2010.

They found that 2,103 had never use cannabis, 975 had used the drug in the past but were not current users, and 579 (over 10%) had inhaled or ingested it in the past month.

Tests showed that current users had 16% lower fasting insulin levels and reduced insulin resistance than those who had never used cannabis. Non-users also had larger waistlines and lower levels of high-density lipoprotein (HDL or ‘good’) cholesterol – both of which are risk factors for type 2 diabetes.

The same benefits were seen among participants who had used the drug in the past but the associations were not as strong, indicating that the effects of cannabis use on insulin levels and insulin sensitivity wear off over time.

“Previous epidemiologic studies have found lower prevalence rates of obesity and diabetes mellitus in marijuana users compared to people who have never used marijuana, suggesting a relationship between cannabinoids and peripheral metabolic processes, but ours is the first to investigate the relationship between marijuana use and fasting insulin, glucose, and insulin resistance,” said lead investigator Mittleman.

Commenting on the study, American Journal of Medicine Editor-in-Chief Joseph S. Alpert, MD, Professor of Medicine at the University of Arizona College of Medicine, Tucson, wrote in an accompanying commentary: “These are indeed remarkable observations that are supported, as the authors note, by basic science experiments that came to similar conclusions.” He added: “We desperately need a great deal more basic and clinical research into the short- and long-term effects of marijuana in a variety of clinical settings such as cancer, diabetes, and frailty of the elderly. I would like to call on the NIH and the DEA to collaborate in developing policies to implement solid scientific investigations that would lead to information assisting physicians in the proper use and prescription of THC in its synthetic or herbal form.”

Diabetes mellitus is a group of autoimmune diseases characterized by defects in insulin secretion resulting in hyperglycemia (an abnormally high concentration of glucose in the blood). There are two primary types of diabetes. Individuals diagnosed with type 1 diabetes (also known as juvenile diabetes) are incapable of producing pancreatic insulin and must rely on insulin medication for survival. Individuals diagnosed with type 2 diabetes (also known as adult onset diabetes) produce inadequate amounts of insulin. Type 2 diabetes is a less serious condition that typically is controlled by diet. Over time, diabetes can lead to blindness, kidney failure, nerve damage, hardening of the arteries and death. The disease is the third leading cause of death in the United States after heart disease and cancer.

Observational trial data published in 2012 in the British Medical Journal previously reported that adults with a history of marijuana use had a lower prevalence of type 2 diabetes and possess a lower risk of contracting the disease than do those with no history of cannabis consumption, even after researchers adjusted for social variables (ethnicity, level of physical activity, etc.) Investigators concluded, “Our analysis of adults aged 20-59 years … showed that participants who used marijuana had a lower prevalence of DM (Diabetes Mellitus) and lower odds of DM relative to non-marijuana users.”

Although subjects who consume marijuana on average have higher average caloric intake levels than non-users, the plant’s use has been associated with lower body-mass index (BMI) and lower rates of obesity.

Abstracts of today’s study, “The Impact of Marijuana Use on Glucose, Insulin, and Insulin Resistance among US Adults,” are online here. NORML has additional information and citations regarding cannabis and diabetes in our Library here.

Behavior Research Center asked respondents whether or not they favored or opposed legalizing the possession of small amounts of marijuana for personal use, 56% responded they favored the idea and only 37% were opposed. Marijuana legalization had support from all age groups, across all counties and with both Democrats and Independents.

Commenting on the results, Behavior Research Center stated: “It is perhaps ironic that as support for same-sex marriage and defelonization of marijuana have long been albatrosses which conservative candidates could hang around the necks of some of their moderate or liberal challengers, it now appears that hard opposition to gay marriage and perhaps even to marijuana liberalization could become issues moderates and liberals can use against their conservative opponents.”

You can view the full results of the poll here.

Researchers at the Meir Medical Center, Department of Gastroenterology and Hepatology in Israel assessed the safety and efficacy of inhaled cannabis versus placebo in 21 subjects with Crohn’s disease who were nonresponsive to conventional treatments.

Eleven participants smoked standardized cannabis cigarettes containing 23 percent THC and 0.5 percent CBD (cannabidiol) twice daily over a period of eight weeks. The other ten subjects smoked placebo cigarettes containing no active cannabinoids.

Investigators reported, “Our data show that 8-weeks treatment with THC-rich cannabis, but not placebo, was associated with a significant decrease of 100 points in CDAI (Crohn’s Disease and activity index) scores.” (The CDIA is a research tool used to quantify the symptoms of Crohn’s disease patients.) Five of the eleven patients in the study group also reported achieving disease remission (defined as a reduction in patient CDAI score by more than 150 points).

Researchers also reported that “no significant side effects” were associated with cannabis inhalation. Subjects in the study group reported improvements in appetite and sleep compared to those in the placebo group. Cannabis inhalation was also associated with “significantly less pain” among the participants.

The study is the first placebo-controlled clinical trial to assess the consumption of cannabis for the treatment of Crohn’s.

Israeli researchers had previously published observational trial data reporting that Crohn’s patients require fewer disease-related surgeries following their use of cannabis.

According to survey data published in 2011 in the European Journal of Gastroenterology and Hepatology, some one-half of Crohn’s disease patients acknowledge having used cannabis to mitigate their disease symptoms.

The study included data from six case-control studies conducted from 1999 to 2012 in the United States, Canada, the United Kingdom, and New Zealand, with a subject pool of 2,159 lung cancer cases and 2,985 controls. All of the studies were part of the International Lung Cancer Consortium (ILCCO), an international group of lung cancer researchers with the aim of sharing comparable data from ongoing and recently completed lung cancer studies from different geographical areas and ethnicities.

Dr. Zhang of the University of California, Los Angeles, performed two analyses. One compared all lung cancer cases and all controls, regardless of concurrent or past tobacco use. Then, to reduce confounding by tobacco, she restricted the analysis to those who had never smoked tobacco.

… When compared with cannabis smokers who also used tobacco, habitual pot smokers had no significant increase in cancer risk. In an analysis of marijuana smokers that excluded tobacco smokers, there were no significant differences in any of the comparisons, including habitual vs. nonhabitual use; number of joints smoked per day; duration of up to 20 years or duration of more than 20 years.

The abstract of the presentation, which concludes “Our pooled results showed no significant association between the intensity, duration, or cumulative consumption of cannabis smoke and the risk of lung cancer overall or in never smokers,” is available online here.

Numerous preclinical studies have documented that cannabinoids possess potent anti-cancer properties, including the inhibition of lung cancer cell growth.